CN114286671A - 用于生物递送媒介物的组合物和方法 - Google Patents

用于生物递送媒介物的组合物和方法 Download PDF

Info

Publication number
CN114286671A
CN114286671A CN202080056429.6A CN202080056429A CN114286671A CN 114286671 A CN114286671 A CN 114286671A CN 202080056429 A CN202080056429 A CN 202080056429A CN 114286671 A CN114286671 A CN 114286671A
Authority
CN
China
Prior art keywords
delivery vehicle
lipid
dialkyl
cationic lipid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080056429.6A
Other languages
English (en)
Chinese (zh)
Inventor
马布西吉·艾哈迈德
蒂莫西·戴
伊斯梅尔·哈菲兹
J·梅利特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Particella Inc
Original Assignee
Dnalite Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnalite Therapeutics Inc filed Critical Dnalite Therapeutics Inc
Publication of CN114286671A publication Critical patent/CN114286671A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080056429.6A 2019-06-14 2020-06-12 用于生物递送媒介物的组合物和方法 Pending CN114286671A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861852P 2019-06-14 2019-06-14
US62/861,852 2019-06-14
US201962948095P 2019-12-13 2019-12-13
US62/948,095 2019-12-13
PCT/US2020/037579 WO2020252375A1 (en) 2019-06-14 2020-06-12 Compositions and methods for biological delivery vehicles

Publications (1)

Publication Number Publication Date
CN114286671A true CN114286671A (zh) 2022-04-05

Family

ID=73781318

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080056429.6A Pending CN114286671A (zh) 2019-06-14 2020-06-12 用于生物递送媒介物的组合物和方法

Country Status (8)

Country Link
US (1) US20220296516A1 (https=)
EP (1) EP3982932A4 (https=)
JP (1) JP7772597B2 (https=)
CN (1) CN114286671A (https=)
AU (1) AU2020290516B2 (https=)
CA (1) CA3142949A1 (https=)
IL (1) IL288755A (https=)
WO (1) WO2020252375A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025036297A1 (zh) * 2023-08-11 2025-02-20 浙江海昶生物医药技术有限公司 一种具有靶向性的脂质组合物及其制备方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
EP4259099A1 (en) * 2020-12-14 2023-10-18 Particella, Inc. Biological delivery systems
WO2022260678A1 (en) * 2021-06-11 2022-12-15 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
JPWO2022176953A1 (https=) * 2021-02-17 2022-08-25
WO2022211481A1 (ko) * 2021-04-01 2022-10-06 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
KR102789632B1 (ko) * 2021-04-01 2025-04-01 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
WO2023182812A1 (ko) * 2022-03-22 2023-09-28 주식회사 바이오엔 담즙산염 및 양이온성 펩타이드를 포함하는 단백질 전달용 조성물 및 이의 용도
CN117247359A (zh) * 2022-06-09 2023-12-19 中国科学院广州生物医药与健康研究院 一种树状样脂质化合物、脂质体、脂质复合物、脂质纳米颗粒及其应用
WO2024006863A1 (en) * 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CN118356505A (zh) * 2023-01-10 2024-07-19 复旦大学 含末端羟基的peg化纳米载体在制备规避人体预存抗peg抗体的药物制剂中的用途
AU2023457271A1 (en) * 2023-06-28 2025-12-18 Global Life Sciences Solutions Canada Ulc Lipid nanoparticle formulations for cell therapy and related methods
WO2025021286A1 (en) * 2023-07-23 2025-01-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. A drug delivery system for increased endosomal escape
US20250082776A1 (en) * 2023-08-31 2025-03-13 Massachusetts Institute Of Technology Polyanion coated lipid nanoparticles and methods of use thereof
PL248770B1 (pl) * 2023-11-23 2026-01-26 Politechnika Wroclawska Bilosomy o dodatnim ładunku i sposób ich wytwarzania
WO2025151073A1 (en) * 2024-01-10 2025-07-17 Agency For Science, Technology And Research Composition and nanoparticle suitable for use in the delivery of a therapeutic agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
WO2011075656A1 (en) * 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2012113803A1 (en) * 2011-02-22 2012-08-30 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
WO2016070082A1 (en) * 2014-10-31 2016-05-06 University Of Utah Research Foundation Compositions and methods for bile acid particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100817024B1 (ko) * 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
US11219634B2 (en) * 2015-01-21 2022-01-11 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
BR112019008481A2 (pt) * 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
EP3558356A2 (en) * 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
WO2019046809A1 (en) * 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
WO2011075656A1 (en) * 2009-12-18 2011-06-23 The University Of British Columbia Methods and compositions for delivery of nucleic acids
WO2012113803A1 (en) * 2011-02-22 2012-08-30 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
WO2016070082A1 (en) * 2014-10-31 2016-05-06 University Of Utah Research Foundation Compositions and methods for bile acid particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JITINDES S. WILKHU等: "Characterization and optimization of bilosomes for oral vaccine delivery", 《JOURNAL OF DRUG TARGETING》, vol. 21, no. 3, pages 291 - 299, XP009532436, DOI: 10.3109/1061186X.2012.747528 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025036297A1 (zh) * 2023-08-11 2025-02-20 浙江海昶生物医药技术有限公司 一种具有靶向性的脂质组合物及其制备方法

Also Published As

Publication number Publication date
CA3142949A1 (en) 2020-12-17
JP2022538797A (ja) 2022-09-06
EP3982932A4 (en) 2023-10-25
IL288755A (en) 2022-02-01
AU2020290516A2 (en) 2022-03-31
EP3982932A1 (en) 2022-04-20
AU2020290516A1 (en) 2022-01-20
US20220296516A1 (en) 2022-09-22
JP7772597B2 (ja) 2025-11-18
WO2020252375A1 (en) 2020-12-17
AU2020290516B2 (en) 2026-01-29

Similar Documents

Publication Publication Date Title
JP7772597B2 (ja) 生物学的送達ビヒクルのための組成物及び方法
US20230023615A1 (en) Compositions and methods for biological delivery vehicles
WO2022260678A1 (en) Compositions and methods for biological delivery vehicles
US20240058454A1 (en) Biological delivery systems
JP2018509387A (ja) 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
AU2012255194B2 (en) Charge triggering of self-organized nanoparticles
JPWO2008120815A1 (ja) がん細胞および癌随伴線維芽細胞への標的化剤
US20190351071A1 (en) Structures and methods for gene therapy
KR20140048404A (ko) 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물
US20210177982A1 (en) Mucus-penetrating peptides, delivery vehicles and methods of therapy
JP2001522871A (ja) 標的化リポゾーム遺伝子送達
KR20250134181A (ko) 핵산의 표적화된 전달을 위한 상승된 중성 지질 및 표적화 모이어티를 포함하는 지질 나노입자
US20240269318A1 (en) Nano-delivery systems comprising modified lipids and use thereof
KR20250094676A (ko) 안티-센스 올리고뉴클레오티드 전달을 위한 지질 나노입자 제형
JP5615509B2 (ja) フコシル化糖鎖産生細胞用物質送達担体
CN117241780A (zh) 生物递送系统
JP5871247B2 (ja) フコシル化糖鎖産生細胞用物質送達担体
US20250339539A1 (en) Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof
KR20130049668A (ko) 저밀도 지단백질 유사 양이온성 나노입자로 된 혈액 뇌 장벽（ｂｂｂ） 수송 벡터
Jin et al. RNA‐Micelles as Self‐Assembling Structures for Efficient Co‐Delivery of Synergistic siRNA and Nucleoside Analogues to Treat CRC Lung Metastasis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Partysera Co.

Address before: California, USA

Applicant before: Dnalite Therapeutics, Inc.